While CAD-1005's clinical progress is a positive catalyst, the company's limited cash runway (~$4M) raises near-term dilution or financing risk. Traders should monitor upcoming capital raises or partnerships; stock reaction may be volatile depending on funding outcome.
Price Chart
Executive Summary
Cadrenal Therapeutics reported financial results for Q4 and full year 2025, highlighting a $3.0M net loss for the quarter (improved from $4.2M in Q4 2024) and $4.0M in cash as of year-end. The company emphasized progress with its lead drug CAD-1005 for heparin-induced thrombocytopenia (HIT), including a completed End-of-Phase 2 meeting with the FDA and encouraging Phase 2 data showing over a 25% absolute reduction in thrombotic events. However, the company is evaluating financing options as cash may not support planned Phase 3 development.
Key Financial Metrics
Key Facts
- Q4 2025 net loss was $3.0M vs. $4.2M in Q4 2024
- Full-year 2025 net loss was $13.2M vs. $10.7M in 2024
- Cash and equivalents: $4.0M as of December 31, 2025, down from $10.0M in 2024
- Completed FDA End-of-Phase 2 meeting for CAD-1005; Phase 3 protocol being updated
- Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005 vs. placebo
- Company evaluating financing and strategic alternatives to fund Phase 3
Financial Impact
Cash burn of $6.0M over 2025; R&D decreased to $4.1M from $4.2M; G&A increased to $9.4M from $6.8M
Risk Factors
- Insufficient cash to fund Phase 3 trial without dilutive financing
- FDA may require larger or longer Phase 3 trial than expected, increasing cost and timeline
- Phase 2 success may not translate to Phase 3 due to small sample or endpoint limitations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265537 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | 8-K | $0.9723 | awaiting T+60 | — | $0.9298 (−4.37%) |
Aug 31, 2026 8w ago | 8-K | $1.75 | awaiting T+60 | — | $0.9298 (−46.87%) |
Jul 21, 2026 13w ago | 8-K | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9298 (−57.15%) |
Jul 21, 2026 13w ago | EFFECT | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9298 (−57.15%) |
Jul 1, 2026 16w ago | Press Release | $3.60 $1.12 | ▲ +68.89% | ▲ +71.94% | $0.9298 (+74.17%) |
Jun 29, 2026 16w ago | 8-K | $3.34 $1.32 | ▼ −60.48% | ▼ −64.04% | $0.9298 (−72.16%) |
Jun 18, 2026 18w ago | 8-K | $3.50 $1.06 | ▼ −69.71% | ▼ −71.61% | $0.9298 (−73.43%) |
Jun 15, 2026 18w ago | 144 | $3.04 $1.18 | ▲ +61.18% | ▲ +62.18% | $0.9298 (+69.41%) |
May 7, 2026 24w ago | Press Release | $6.02 $1.96 | ▼ −67.44% | ▼ −71.27% | $0.9298 (−84.55%) |
Apr 30, 2026 25w ago | 8-K | $6.67 $2.06 | ▼ −69.12% | ▼ −72.22% | $0.9298 (−86.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers